Published in JAMA on February 26, 1973
Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother (1980) 3.54
Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother (1996) 3.40
Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis. Antimicrob Agents Chemother (1974) 3.06
Synergism of carbenicillin and gentamicin against enterococci. Antimicrob Agents Chemother (1973) 2.60
Antimicrobial susceptibility of Streptococcus mutans isolated from patients with endocarditis. Antimicrob Agents Chemother (1974) 2.37
Antimicrobial therapy of experimental enterococcal endocarditis. Antimicrob Agents Chemother (1975) 1.75
Comparative synergistic activity of nafcillin, oxacillin, and methicillin in combination with gentamicin against. Antimicrob Agents Chemother (1975) 1.50
Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis. Antimicrob Agents Chemother (1981) 1.43
Synergy of penicillin-netilmicin combinations against enterococci including strains highly resistant to streptomycin or kanamycin. Antimicrob Agents Chemother (1977) 1.34
Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother (1990) 1.21
Synergism of cefazolin-gentamicin against enterococci. Antimicrob Agents Chemother (1976) 1.21
Penicillin-netilmicin synergism against Streptococcus faecalis. Antimicrob Agents Chemother (1978) 1.19
Studies of cephalothin: aminoglycoside synergism against enterococci. Antimicrob Agents Chemother (1975) 1.18
Optimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis. Antimicrob Agents Chemother (1992) 0.99
Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. Antimicrob Agents Chemother (1982) 0.94
Synergism of oxacillin and gentamicin against enterococci. Antimicrob Agents Chemother (1975) 0.91
A simple test to demonstrate antibiotic synergism. J Clin Pathol (1975) 0.91
Streptoccocus faecalis endocarditis: an emerging problem? Postgrad Med J (1978) 0.83
Infectious disease emergencies. Part II: patients presenting with cardiac decompensation or circulatory insufficiency (shock). West J Med (1976) 0.79
Enterococcal endocarditis: duration and mode of treatment. Trans Am Clin Climatol Assoc (1978) 0.78
Letter: Enterococcal endocarditis. Can Med Assoc J (1974) 0.75
Infective endocarditis: prevention, diagnosis and treatment. Can Fam Physician (1977) 0.75
Infectious diseases: annual review of significant publications. Postgrad Med J (1974) 0.75
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis (1979) 4.70
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Antimicrobial-drug resistance. N Engl J Med (1996) 4.07
Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) (1977) 4.05
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother (1993) 3.80
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol (1971) 3.59
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med (1980) 3.59
Synergy of penicillin and gentamicin against Enterococci. J Infect Dis (1971) 3.55
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother (1977) 3.27
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet (1975) 3.00
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 2.99
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
The enterococcus: "putting the bug in our ears". Ann Intern Med (1987) 2.59
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med (1974) 2.39
Antimicrobial synergism--an elusive concept. J Infect Dis (1979) 2.39
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Recovery of resistance (R) factors from a drug-free community. Lancet (1969) 2.26
Drug therapy: The newer cephalosporins. N Engl J Med (1976) 2.20
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10
Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation (1974) 2.08
Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) (1970) 2.07
Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med (1977) 2.07
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
Genitourinary tuberculosis. Clinical features in a general hospital population. Am J Med (1977) 1.91
Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest (1978) 1.90
Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin. Antimicrob Agents Chemother (1974) 1.86
In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother (1994) 1.82
Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.75
Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother (1983) 1.74
Enterococcal infections in patients treated with moxalactam. Rev Infect Dis (1983) 1.72
Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother (1990) 1.71
Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin. Antimicrob Agents Chemother (1981) 1.67
Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother (1998) 1.63
Patterns and mechanisms of antibiotic resistance. Med Clin North Am (1978) 1.63
CT-guided percutaneous aspiration and drainage of abscesses. AJR Am J Roentgenol (1980) 1.61
Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg (1977) 1.60
Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci. Antimicrob Agents Chemother (1979) 1.60
Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol (1988) 1.58
In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 1.56
Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med (1982) 1.55
Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis (1982) 1.54
Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.53
Fulminant Mycoplasma pneumoniae infection. Report of a fatal case, and a review of the literature. Am Rev Respir Dis (1980) 1.52
Aminoglycoside-modifying enzymes among clinical isolates of Acinetobacter calcoaceticus subsp. anitratus (Herellea vaginicola): explanation for high-level aminoglycoside resistance. Antimicrob Agents Chemother (1979) 1.52
Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother (1989) 1.47
Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother (1984) 1.45
Antimicrobial susceptibility of flavobacteria. Antimicrob Agents Chemother (1978) 1.44
In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother (1996) 1.42
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Efficacy of oxacillin and ampicillin-sulbactam combination in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother (1990) 1.40
In-vivo acquisition of two different types of aminoglycoside resistance by a single strain of Klebsiella pneumoniae causing severe infection. Ann Intern Med (1982) 1.39
Evidence of plasmid-mediated production of aminoglycoside-modifying enzymes not previously described in Acinetobacter. Antimicrob Agents Chemother (1980) 1.39
Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (1997) 1.39
Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-formimidoyl thienamycin against beta-lactamase-producing, carbenicillin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 1.38
Hemophilus influenzae in hospitalized adults: current perspectives. Am J Med (1980) 1.38
Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis (1982) 1.36
Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother (1991) 1.35
In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 1.33
In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother (1989) 1.33
Unusual serum lipoprotein abnormality induced by the vehicle of miconazole. N Engl J Med (1977) 1.32
Home intravenous antibiotic therapy: a team approach. Ann Intern Med (1983) 1.30
Endocarditis due to resistant viridans streptococci during oral penicillin chemoprophylaxis. N Engl J Med (1979) 1.29
CT detection and aspiration of abdominal abscesses. AJR Am J Roentgenol (1977) 1.25
Cephalosporins. Annu Rev Med (1981) 1.25
Pharmacokinetics of vancomycin. J Antimicrob Chemother (1984) 1.24
Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis (1989) 1.23
Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother (1998) 1.22
A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis. J Infect Dis (1980) 1.21
Cephalosporin-aminoglycoside synergism in experimental enterococcal endocarditis. Antimicrob Agents Chemother (1976) 1.21
Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis (1993) 1.21
Comparative in vitro activity of SM7338, a new carbapenem antimicrobial agent. Antimicrob Agents Chemother (1989) 1.19
Penicillin-netilmicin synergism against Streptococcus faecalis. Antimicrob Agents Chemother (1978) 1.19
Studies of cephalothin: aminoglycoside synergism against enterococci. Antimicrob Agents Chemother (1975) 1.18